Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · DAXOR CORP (DXR)

Daxor Gets FDA 510(k) Clearance for Next-Generation Rapid Blood Volume Analyzer

Neutral Impact 3 of 5 product/contract Written later

Daxor Corporation announced FDA 510(k) clearance (K251087) for its next-generation, rapid, portable lab-based Blood Volume Analyzer (BVA), according to a press release dated August 7, 2025. The filing does not include financial results or a financial impact estimate, so its effect on shareholders is not quantified.

Key points

  • FDA 510(k) clearance was granted under number K251087 for the new Daxor BVA device.
  • The company says the device provides results three times faster than its predecessor and weighs 7 lbs.
  • The system was developed under contract with the U.S. Department of Defense, including the U.S. Army and the Defense Health Agency.
  • The company states that more than 75,000 tests have shipped to date.

The filing

CompanyDAXOR CORP (DXR)
Form8-K, current report
Filed with the SECAug 7, 2025, 8:26 AM ET
Accession number0001641172-25-022513

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:51 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 07, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.